Eli Lilly and Company (LLY)

Total asset turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	45,042,700	40,863,300	38,922,800	35,932,100	34,124,100	32,072,500	29,515,500	27,691,400	28,541,400	29,239,500	29,070,700	29,322,800	28,318,400	27,758,500	26,726,300	25,485,600	24,539,800	23,213,800	22,949,800	23,087,100
Total assets	US$ in thousands	78,714,900	75,606,900	71,874,800	63,943,500	64,006,300	57,915,500	54,814,000	53,163,000	49,489,800	47,461,500	47,063,600	46,919,300	48,806,000	48,187,000	47,809,000	46,838,300	46,633,100	43,946,000	41,967,000	41,102,800
Total asset turnover		0.57	0.54	0.54	0.56	0.53	0.55	0.54	0.52	0.58	0.62	0.62	0.62	0.58	0.58	0.56	0.54	0.53	0.53	0.55	0.56

December 31, 2024 calculation

Total asset turnover = Revenue (ttm) ÷ Total assets
= $45,042,700K ÷ $78,714,900K
= 0.57

Eli Lilly and Company's total asset turnover ratio has shown some fluctuations over the period from March 31, 2020, to December 31, 2024. The total asset turnover ratio measures the efficiency of a company in generating sales from its assets. A higher total asset turnover ratio indicates that the company is effectively utilizing its assets to generate sales revenue.

In this case, Eli Lilly and Company's total asset turnover ratio ranged from 0.52 to 0.62 during the period under consideration. The ratio reached its highest point of 0.62 in March 31, 2022, June 30, 2022, and September 30, 2022. This suggests that the company was able to generate $0.62 in sales revenue for every $1 of assets during those quarters, indicating efficient asset utilization.

However, the total asset turnover ratio experienced a decline to 0.52 in March 31, 2023, which indicates a decrease in sales generated from its assets during that period. The ratio recovered slightly in the subsequent quarters but remained below the peak levels reached in 2022.

Overall, while there were fluctuations in Eli Lilly and Company's total asset turnover ratio over the period analyzed, the company generally maintained a moderate level of efficiency in generating sales from its assets. Further analysis of the company's financial performance and operational efficiency would provide a more comprehensive understanding of its asset utilization dynamics.